Feature | November 22, 2013

Lexiscan, Adenoscan May Put Patients at Risk for Heart Attack, Death

radiopharmaceuticals and tracers nuclear molecular imaging FDA lexiscan
November 22, 2013 — The U.S. Food and Drug Administration (FDA) is warning healthcare professionals of the rare but serious risk of heart attack and death with use of the cardiac nuclear stress test agents Lexiscan (regadenoson) and Adenoscan (adenosine). The FDA has approved changes to the drug labels to reflect these serious events and updated recommendations for use of these agents. At this time, data limitations prevent FDA from determining if there is a difference in risk of heart attack or death between Lexiscan and Adenoscan.
 
The Warnings and Precautions section of the Lexiscan and Adenoscan labels previously contained information about the possible risk of heart attack and death with use of these drugs. However, recent reports of serious adverse events in the FDA Adverse Event Reporting System (FAERS) database and the medical literature prompted approval changes to the drug labels to include updated recommendations for use.
 
Lexiscan and Adenoscan are FDA-approved for use during cardiac nuclear stress tests in patients who cannot exercise adequately. Lexiscan and Adenoscan help identify coronary artery disease (CAD). They do this by dilating the arteries of the heart and increasing blood flow to help identify blocks or obstructions in the heart’s arteries. Lexiscan and Adenoscan cause blood to flow preferentially to the healthier, unblocked or unobstructed arteries, which can reduce blood flow in the obstructed artery. In some cases, this reduced blood flow can lead to a heart attack.?
 
Doctors should screen all nuclear stress test candidates for their suitability to receive Lexiscan or Adenoscan, as well as avoid using these drugs in patients with signs or symptoms of unstable angina or cardiovascular instability, as these patients may be at greater risk for serious cardiovascular adverse reactions. Cardiac resuscitation equipment and trained staff should be available before administering Lexiscan or Adenoscan.
 
Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program.
 
For more information: www.fda.gov

Related Content

New PET-CT Scan Improves Detection in Rare Cardiac Condition
News | PET-CT| July 25, 2017
Using a new imaging technique that can diagnose cardiac sarcoidosis much more accurately than traditional tests,...
Sponsored Content | Videos | Business| July 13, 2017
Randall Thompson, M.D., professor of medicine at the University of Missouri, Kansas City, attending cardiologist, Mid
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging| July 07, 2017
Blood clots in veins and arteries can lead to heart attack, stroke and pulmonary embolism, which are major causes of...
Sponsored Content | Videos | Clinical Decision Support| June 29, 2017
Rami Doukky, M.D., system chair, Division of Cardiology, professor of medicine, Cook County Health and Hospitals Syst
cardiac nuclear myocardial perfusion imaging (MIP) exam guidelines for women
News | Nuclear Imaging| June 15, 2017
June 15, 2017 — The American Society of Nuclear Cardiology (ASNC) has published an updated consensus statement on evi
Philips Dosewise portal allows X-ray radiation dose tracking for individual patients

An example of radiation dose tracking software is Philips Dosewise portal, which allows X-ray radiation dose tracking for individual patients by modality, body region and exam type.

Feature | Radiation Dose Management| June 13, 2017 | Dominic Siewko
In recent years, radiation dose management awareness has heightened across the healthcare industry to address growing
MIM Software Inc. Announces Updates to MIM Encore
Technology | Remote Viewing Systems| May 31, 2017
MIM Software Inc. recently announced significant updates to its MIM Encore solution for viewing nuclear medicine images...
News | Enterprise Imaging| May 25, 2017
At the 2017 annual meeting of the Society for Imaging Informatics in Medicine (SIIM), June 1-3 in Pittsburgh, Konica...
Lantheus and GE Healthcare Sign Agreement for Worldwide Development, Commercialization of Flurpiridaz F-18
News | Radiopharmaceuticals and Tracers| May 22, 2017
Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., and GE Healthcare announced the signing of a...
Study Reveals Low Adoption of IAEA Recommendations for Reduced Nuclear Cardiology Radiation Exposure
News | Radiation Dose Management| May 12, 2017
A study in 65 countries has revealed low adoption of International Atomic Energy Agency (IAEA) recommendations to...
Overlay Init